Evidence guide · UK
Iron, B12 and folate on GLP-1 medicines: what the new anaemia data show
A 17 November 2026 study of 135,216 adults found nutritional-deficiency anaemia in 2% to 3% of tirzepatide and GLP-1 users in a year. What the iron and B12 evidence shows, who should get a blood test, and the rules in the UK, US, UAE and South Africa.
Review type: research summary. This page summarises published research and product labels, cited below.
GLP-1 medicines such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) cut appetite, and people eating less have started asking whether they need iron, vitamin B12 or folate. On 17 November 2026, Diabetes Research and Clinical Practice published a study of 135,216 adults with type 2 diabetes and overweight or obesity that compares diagnosed nutritional-deficiency anaemia in the first year on tirzepatide and on other GLP-1 medicines. It occurred in 2.13% of tirzepatide users and 2.84% of people on other GLP-1 medicines.
Short answer: anaemia from low iron, B12 or folate was uncommon in the first year in this study, and slightly less common on tirzepatide, mainly because of less iron-deficiency anaemia. The study did not compare people on these medicines with people not taking them, so it cannot say how much of that anaemia the medicines caused. Smaller studies suggest semaglutide may reduce iron absorption in some people. None of this supports taking iron just in case. If you feel unusually tired, breathless or pale on a GLP-1 medicine, ask for a blood test rather than buying a supplement.
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.
What the new study found
Tu and colleagues used TriNetX, a large network of electronic health records, to identify adults with type 2 diabetes and overweight or obesity who started tirzepatide or another GLP-1 medicine between 1 January 2022 and 31 August 2026. People who had used either treatment before, or who already had nutritional-deficiency anaemia, type 1 diabetes or bariatric surgery, were excluded. After 1:1 propensity score matching, each group had 67,608 people, and the authors followed them for a year.
The main outcome was a diagnosis of iron, vitamin B12 or folate deficiency anaemia. It was recorded in 1,440 tirzepatide users (2.13%) and 1,917 people on other GLP-1 medicines (2.84%), a hazard ratio of 0.88 (95% CI 0.83 to 0.95). Iron-deficiency anaemia was less common on tirzepatide (hazard ratio 0.87, 0.81 to 0.93). The results for B12-deficiency anaemia (1.07, 0.83 to 1.38) and folate-deficiency anaemia (0.98, 0.56 to 1.71) were inconclusive. The authors say residual confounding and differences in follow-up and in how diagnoses were recorded limit any causal reading.
Three limits matter for readers. The study counted diagnoses, so anaemia that nobody checked for is missing. It compared two groups of GLP-1 users, so it does not show the risk compared with taking neither medicine. And everyone had type 2 diabetes, so the figures may not apply to people using these medicines for weight loss alone.
Other signals: absorption, haemoglobin and stores
A Croatian pilot study gave 51 adults with type 2 diabetes an oral iron absorption test (a single 350 mg ferrous fumarate capsule after a 12-hour fast) before starting weekly semaglutide injections and again 10 weeks later. The median relative reduction in iron absorption was 13%, and 9 of the 51 (17.6%) absorbed at least 30% less. There was no separate comparison group, and the authors did not systematically assess whether diet changed after semaglutide started.
A retrospective study from King Abdulaziz University in Jeddah reviewed 700 people prescribed semaglutide (69.7%) or liraglutide (30.3%), most for diabetes, with a median follow-up of nine months. Haemoglobin fell by a median of 0.2 g/dL, and 59 people (8.4%) developed anaemia, defined there as haemoglobin below 11 g/dL. Ferritin, the main measure of iron stores, did not change significantly. There was no comparison group, and the study did not account for people taking iron supplements or other medicines that affect haemoglobin or ferritin.
A 2026 narrative review of six studies covering 480,825 adults reported that GLP-1 users had ferritin 26% to 30% lower than people taking SGLT2 inhibitors (another class of diabetes medicine), that more than 60% ate less calcium and iron than estimated requirements, and that thiamine and B12 deficits increased over time. The authors say the data are mainly observational and cannot establish that the medicines caused the shortfalls. A 2026 case report describes a 52-year-old man who presented with severe iron-deficiency anaemia (haemoglobin 81 g/L) six weeks after starting semaglutide for weight loss. Oral and parenteral iron over the next six months did not restore his blood count or iron stores until semaglutide was stopped. That is one patient, and it cannot show how often this happens.
Iron deficiency on GLP-1 medicines: Limited
The signals point the same way: lower food intake, possibly lower absorption, and lower ferritin in some studies. But the evidence comes from one small uncontrolled absorption study, retrospective records and a single case, and the Jeddah study found no significant change in ferritin. A 2026 review in Nutrients, one of whose authors advises Novo Nordisk, the maker of semaglutide, says iron deficiency and iron-deficiency anaemia currently appear to be uncommon adverse effects of these medicines, and that prescribing should not be unjustifiably restricted because of that possible and modest risk.
Tirzepatide versus other GLP-1 medicines: Limited
The new study is large, and its result is precise, but it is a single observational comparison of diagnoses. The absolute gap was 0.71 percentage points over a year. It is not a reason to choose or switch medicine, which depends on far more than anaemia risk.
Vitamin B12 and folate: Insufficient
The new study could not tell whether B12 or folate anaemia differed between the two medicines. For people with type 2 diabetes, metformin matters more. The MHRA says decreased vitamin B12 is a common side effect of metformin, and that the risk rises with higher doses, longer treatment and existing risk factors. It advises checking B12 in people on metformin who have symptoms of deficiency and considering periodic checks in those with risk factors. The NHS also lists some medicines, including proton pump inhibitors, among the causes of low B12 or folate.
Compounded tirzepatide with added B12
Some compounded tirzepatide products are sold as fixed combinations with forms of vitamin B12. A 2026 laboratory study by employees of Eli Lilly, which makes Mounjaro and Zepbound, found a previously unidentified impurity in samples of these products, formed by a reaction between tirzepatide and certain forms of B12. The clinical effects of the impurity are unknown, and the authors work for the maker of the approved product. Adding B12 to an injection does not show that the person needs it.
If you are on a GLP-1 medicine
The NHS lists tiredness, lack of energy, shortness of breath, noticeable heartbeats, paler skin and headaches among the symptoms of iron-deficiency anaemia, and tiredness, pins and needles, a sore red tongue and mouth ulcers among the symptoms of low B12 or folate. A GP can check with a full blood count, which also picks up B12 or folate anaemia. Iron-deficiency anaemia is not always about diet: the NHS lists heavy periods and bleeding from the stomach or bowel among the common causes, so a cause should be found before treatment. If iron tablets are needed, the NHS says they are usually taken for about six months.
The NHS says most people can get the iron they need from a varied diet, that 8.7 mg a day is needed by men aged 19 and over and by women aged 50 and over, and 14.8 mg a day by women aged 19 to 49 (women still having periods after 50 may need 14.8 mg), and that 17 mg a day or less from supplements is unlikely to cause harm. Doses over 20 mg can cause constipation, nausea, vomiting and stomach pain. Very high doses can be fatal, particularly in children, so iron supplements should be kept out of their reach. The NHS also says large amounts of tea, coffee and milk can make it harder to absorb iron.
Infante and colleagues propose a full blood count and iron tests before starting a GLP-1 medicine in people with symptoms or a past iron deficiency and in others at risk, with periodic checks afterwards. They describe these as practical suggestions drawn from general iron-deficiency guidance, not yet studied in trials of GLP-1 users.
Our view
- Do not take iron just in case. In the new study, about 2% to 3% of users were diagnosed with nutritional-deficiency anaemia in the first year, and the NHS says iron doses over 20 mg can cause constipation, nausea and stomach pain.
- Ask for a blood test if you feel more tired or breathless than the weight loss explains, or if you have heavy periods, follow a vegetarian or vegan diet, have had bowel problems or take metformin or a proton pump inhibitor.
- If you take metformin as well as a GLP-1 medicine, ask whether your B12 has been checked.
- Prioritise iron-rich foods such as meat, beans, lentils and fortified cereals within the protein you are already trying to eat.
- Treat a product that bundles B12 into a GLP-1 injection as a reason for caution, not reassurance.
UK rules
In the UK, iron supplements sold as food supplements may use authorised health claims such as "iron contributes to normal formation of red blood cells and haemoglobin", and vitamin B12 products may say "vitamin B12 contributes to normal red blood cell formation". These describe a nutrient's normal role, not a treatment for anaemia. Report suspected side effects of a GLP-1 medicine through the MHRA Yellow Card scheme. If a food supplement makes you unwell, stop it and contact a healthcare professional; concerns about its safety, labelling or claims can be reported to the local authority, which reports food safety incidents to the Food Standards Agency.
FAQ
Does Mounjaro or Ozempic cause anaemia?
There are signals, mostly from observational data, that GLP-1 medicines may lower iron intake or absorption in some people. In a 2026 study of 135,216 adults with type 2 diabetes, about 2% to 3% were diagnosed with anaemia from low iron, B12 or folate in the first year, slightly fewer on tirzepatide. The study cannot show the medicines caused it.
Should I take an iron supplement on a GLP-1 medicine?
Not without a blood test showing you need it. Iron deficiency has several causes, including blood loss, that need checking, and iron tablets often cause constipation and nausea.
Do I need B12 injections with tirzepatide?
The new study found no clear difference in B12-deficiency anaemia between tirzepatide and other GLP-1 medicines, and none of the studies here support routine B12 for everyone on tirzepatide. People on metformin have a higher risk of low B12, and the MHRA advises checking levels when symptoms suggest deficiency.
What blood tests should I ask for?
A full blood count checks for anaemia, and ferritin measures iron stores. B12 and folate can be checked if the blood count or symptoms suggest it. Your doctor will decide which tests fit your history.
Sources
These are the documents this page relies on.
- Tu KC, Huang KH, Liu MY, Lin YM, Wu JY. Tirzepatide and risk of nutritional deficiency anemia compared with GLP-1 receptor agonists in adults with type 2 diabetes and overweight or obesity. Diabetes Res Clin Pract. Published online 17 November 2026:113675. doi:10.1016/j.diabres.2026.113675Diabetes Research and Clinical Practice (PubMed 43044770)
- Melis P, Lucijanic M, Kranjcec B, Cigrovski Berkovic M, Marusic S. The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus: a pilot study. Diabetes Obes Metab. 2025;27(6):3542-3545Diabetes, Obesity and Metabolism (PubMed 40116342)
- Almuammar SA, Alzahrani HK. GLP-1 analog therapy and hemoglobin levels: insights from a retrospective study. Saudi Med J. 2025;46(8):907-912Saudi Medical Journal (PubMed 40840939)
- Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review. Clin Obes. 2026;16(1):e70070Clinical Obesity (PubMed 41549912)
- Šimić S, Ćurić J, Sedlić F, Mustapić S. Where did the iron go? A case report of a patient with severe iron deficiency anemia despite parenteral and oral iron supplementation due to semaglutide application. AME Case Rep. 2026;10:178AME Case Reports (PubMed 42871539)
- Infante M, Ricordi C, Pacifici F, et al. Ironing out possible micronutrient deficiencies associated with incretin receptor agonist-based therapies: proposed practical strategies to prevent and manage iron deficiency. Nutrients. 2026;18(13):2038Nutrients (PubMed 42451041)
- Jordan B, Arbogast L, Clemens M, Huang L, Snyder M. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opin Drug Saf. 2026;25(5):837-845Expert Opinion on Drug Safety (PubMed 42010938)
- Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk (Drug Safety Update, 20 June 2022)Medicines and Healthcare products Regulatory Agency
- Iron deficiency anaemiaNHS
- Vitamins and minerals: ironNHS
- Vitamin B12 or folate deficiency anaemiaNHS
- Commission Regulation (EU) No 432/2012, Annex: list of permitted health claims (as retained in Great Britain)legislation.gov.uk
- Yellow Card: report a side effectMedicines and Healthcare products Regulatory Agency
- Food supplements: guidance for consumers (published 25 June 2026)GOV.UK